Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
294 results about "Protein L" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Protein L was first isolated from the surface of bacterial species Peptostreptococcus magnus and was found to bind immunoglobulins through L chain interaction, from which the name was suggested. It consists of 719 amino acid residues. The molecular weight of Protein L purified from the cell walls of Peptostreptoccus magnus was first estimated as 95kD by SDS-PAGE in the presence of reducing agent 2-mercaptoethanol, while the molecular weight was determined to 76kD by gel chromotography in the presence of 6 M guanidine HCl. Protein L does not contain any interchain disulfide loops, nor does it consist of disulfide-linked subunits. It is an acidic molecule with a pI of 4.0. Unlike Protein A and Protein G, which bind to the Fc region of immunoglobulins (antibodies), Protein L binds antibodies through light chain interactions. Since no part of the heavy chain is involved in the binding interaction, Protein L binds a wider range of antibody classes than Protein A or G. Protein L binds to representatives of all antibody classes, including IgG, IgM, IgA, IgE and IgD. Single chain variable fragments (scFv) and Fab fragments also bind to Protein L.
Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
ActiveUS20140356322A1Organic active ingredientsPeptide/protein ingredientsProtein targetEnhanced degradation
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and / or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation / inhibition of targeted polypeptides.
Owner:YALE UNIV +2
Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
Owner:SANOFI SA
Heterodimer Binding Proteins and Uses Thereof
InactiveUS20130129723A1Animal cellsFused cellsImmunoglobulin Joining RegionImmunoglobulin light chain
The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.
Owner:EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC
Half immunoglobulin binding proteins and uses thereof
InactiveUS20120201746A1Altered pharmacokineticAltered pharmacodynamic propertyIn-vivo radioactive preparationsAntibody mimetics/scaffoldsAntibody Binding SiteBinding site
The invention provides compositions, methods, and kits related to half-Ig binding proteins that include a functional antibody binding site and a CH3 domain wherein the CH3 domain includes at least one mutation to inhibit CH3-CH3 dimerization.
Owner:ABBVIE INC
Expression technology for proteins containing a hybrid isotype antibody moiety
Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and / or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
Owner:MERCK PATENT GMBH
Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
Provided herein are binding proteins comprising one or more immunoglobulin Fc region hinge, CH2, and / or CH3 domain wherein one or more hinge and / or constant region CH2 and / or CH3 domain is modified to alter the binding protein's binding affinity and / or specificity for a cognate receptor (e.g., an Fc receptor) and / or to impart one or more new binding specificity(ies) to the hinge and / or constant region that the corresponding unmodified immunoglobulin does not possess (e.g., affinity for distinct class of cognate receptor distinct from the class of cognate receptor to which the unmodified binding protein specifically binds). Binding proteins according to the present invention include, for example, modified antibodies, antibody fragments, recombinant binding proteins, and molecularly engineered binding domain-immunoglobulin fusion proteins, including small modular immunopharmaceutical products (SMIP™ products).
Owner:TRUBION PHARM INC
Anti-PD-1 humanized monoclonal antibody and application thereof
ActiveCN105175544AHigh affinityPlay effectivelyImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsMolecular ImmunologyNucleotide
The invention discloses an anti-PD-1 humanized monoclonal antibody and application thereof, belonging to the technical field of molecular immunology. The anti-PD-1 humanized monoclonal antibody provided by the invention contains a light chain and a heavy chain, wherein the amino acid sequence of the light chain is as shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain is as shown in SEQ ID NO.4 or SEQ ID NO.6. Meanwhile, the invention also provides a nucleotide sequence coding the light chain and heavy chain. The anti-PD-1 humanized monoclonal antibody provided by the invention has very high affinity with human PD-1 protein, and can interdict PD-1 / PD-L1 combination so as to promote T cell proliferation and IFN-gamma secretion.
Owner:ANHUI RUBIOX VISION BIOTECH
Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
ActiveUS20140037621A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenIgG.heavy chain
The invention provides constant regions incorporating a cysteine mutation and linked to a μ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and μ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.
Owner:JN BIOSCI
Human TNF receptor fusion protein
The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.
Owner:F HOFFMANN LA ROCHE INC
IL-1 Binding Proteins
ActiveUS20100221179A1High affinityImprove the level ofAntibacterial agentsFungiDiseaseAntigen binding
The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, e.g., in a human subject suffering from a disorder in which IL-1α activity is detrimental.
Owner:ABBVIE INC
Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
ActiveUS20140051833A1Reduces and eliminates bindingImprove abilitiesHybrid immunoglobulinsImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulin heavy chainHeavy chain
The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified / mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).
Owner:NOVIMMUNE
Heteromultimers with reduced or silenced effector function
ActiveUS20160102135A1Reduce the binding forceReduced effector functionNervous disorderBacteriaHinge regionProtein L
Provided herein are heteromultimer constructs with reduced or silenced effector function. In an embodiment is provided a heteromultimer construct comprising an IgG Fc construct having a first and a second Fc polypeptide, each Fc polypeptide comprising a modified lower hinge region wherein: the modified lower hinge region of said first Fc polypeptide comprises at least one amino acid modification, the modified lower hinge region of said second Fc polypeptide comprises at least one amino acid modification which is different from at least one amino acid modification of said first Fc polypeptide, and the IgG Fc construct displays reduced binding to all Fcγ receptors and to C1q protein as compared to a corresponding parent IgG Fc construct. Also provided are methods of producing such heteromultimer constructs, and methods of reducing ADCC for an antibody construct by reducing effector function.
Owner:ZYMEWORKS INC
Double antibody latex enhanced retinol binding protein detection kit
The invention relates to a double antibody latex enhanced retinol binding protein detection kit. More specifically, the invention discloses a double antibody coating latex enhanced immunoturbidimetry kit for detecting retinol binding protein. The kit contains a reagent 1, a reagent 2 and a calibrator. Paring monoclonal antibody A and B are respectively coated on latex particles. Coated antibody is bonded with RBP to be detected, and a plurality of bonders are aggregated together to form detectable turbidity change. The detection kit provided by the invention has high sensitivity, can be used to detect urine samples and serum samples and can be used as nutritive index to detect RBP in serum. Simultaneously, through the detection of RBP in urine, the kit is sensitive to the damage degree of renal proximal tubule.
Owner:BEIJING STRONG BIOTECH INC
Antibodies to matrix metalloproteinase 9
ActiveUS20130224210A1Antibacterial agentsOrganic active ingredientsHeavy chainAntigen Binding Fragment
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
Owner:GILEAD BIOLOGICS
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
ActiveUS8052974B2Proper fluidityReduce absorptionSugar derivativesViral antigen ingredientsCell specificViral infection
The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of viral infections.
Owner:JANSSEN VACCINES & PREVENTION BV
Methods of generating libraries and uses thereof
ActiveUS8685897B2High affinityHigh reactivityImmunoglobulins against growth factorsFermentationHeavy chainActivation-induced (cytidine) deaminase
Owner:ANAPTYSBIO INC
Anti-CD19 full humanized antibody or antibody segment as well as method and application thereof
ActiveCN107880128ATo achieve the purpose of healingPolypeptide with localisation/targeting motifImmunoglobulin superfamilyComplementarity determining regionHeavy chain
The invention discloses an anti-CD19 full humanized antibody or antibody segment as well as a method and an application thereof. The antibody or the antibody segment contains a heavy chain and a lightchain, wherein the heavy chain and the light chain comprise variable regions; the variable regions comprise complementary determining regions; the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain are separately represented by HCDR1, HCDR2 and HCDR3; the complementary determining regions CDR1, CDR2 and CDR3 of the light chain are separately represented by LCDR1, LCDR2 and LCDR3; the amino acid sequence of the HCDR1 comprises SED ID NO: 3; the amino acid sequence of the HCDR2 comprises SEQ ID NO: 4; the amino acid sequence of the HCDR3 comprises SEQ ID NO: 5; the amino acid sequence of the LCDR1 comprises SEQ ID NO: 6; and the amino acid sequence of the LCDR2 comprises SEQ ID NO: 7. The antibody or the antibody segment can be combined with a humanized CD19 protein with high specificity, and by means of engineered expression integration by means of a chimeric antigen receptor cell technology in a cell T, the obtained chimeric antigen receptor cell T can be used for treating hematological cancers related to expression of CD19.
Owner:CHANGZHOU VELOX PHARMA SCI & TECH CO LTD
Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.
Owner:DUKE UNIV
Pharmaceutical formulation containing immunoglobulin
InactiveUS20120237532A1High throughput generationImprove stabilityAntibody ingredientsImmunoglobulinsComplementarity determining regionImmunoglobulin A
A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs.
Owner:ICON GENETICS
Variable region gene of high affinity monoclonal antibody of tumor necrosis factor and its preparation
The invention discloses a process for preparing variable zone genes of high affinity tumor necrosis factor (TNF) resistant monoclonal antibody (F6 mAb) comprising, using recombinated human TNF immune BALB / c mouse to prepare a plurality of mouse Anti-TNF monoclonal antibody, screening high affinity F6 mAb using indirect ELISA method. By cloning the monoclonal antibody light chain and heavy chain variable zone genes, the monoclonal antibody light chain and heavy chain variable zone gene sequence and amino acid sequence can be obtained, and the unicity of the gene sequence and protein sequence can be confirmed.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Single-domain antigen-binding proteins that bind mammalian IgG
The present application relates to antigen-binding proteins that are capable of binding to mammalian IgG. The frame-work regions of the antigen-binding proteins of the application preferably correspond to those of antibodies naturally that are devoid of light chains as may e.g. be found in camelids. The application further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, to the uses of such immunoadsorbent materials for the purification of mammalian IgG antibodies and for therapeutic apheresis.
Owner:BAC IP
Heterodimer binding proteins and uses thereof
InactiveCN102958942APeptide/protein ingredientsAntibody mimetics/scaffoldsImmunoglobulin light chainActivation cells
The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.
Owner:EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC
Double antibody complex retinol-binding protein assay kit
A retinol-binding protein assay kit in the market at present has good specificity and insufficient sensitivity or has high sensitivity and poor specificity because the purity of antibodies is insufficient or the potency cannot meet the requirement. The invention provides a double antibody complex retinol-binding protein assay kit, which consists of three parts, namely, a reagent R1, a reagent R2 and calibration materials. The reagent R1 is a phosphate buffer system which consists of phosphate buffer solution with the pH of 7.2 to 7.6, polyethylene glycol 6000-8000 and ethylene diamine tetraacetic acid; the reagent R2 is antibody solution which consists of mouse anti-human monoclonal antibody, rabbit anti-human polyclonal antibody, phosphate buffer solution with the pH of 7.2 to 7.6 and the ethylene diamine tetraacetic acid. By adopting a complex antibody of the polyclonal antibody and monoclonal antibody, the sensitivity and high linearity are guaranteed, and the accuracy of the measured result is greatly improved.
Owner:浙江康特生物科技有限公司
Isolating cells expressing secreted proteins
InactiveUS20140072980A1DifferentiateImprove the level ofAnimal cellsBacteriaSurface displayCell based
A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and / or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.
Owner:REGENERON PHARM INC
Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
InactiveUS6348323B1Decorative surface effectsDuplicating/marking methodsAnalyteInsulin-like growth factor binding
The present invention relates to screening or testing for insulin like growth factors, insulin like growth factor binding proteins and / or acid labile subunit by the use of a solid support. Blood is collected onto a solid support, such as paper, and subsequently the analytes of interest are extracted for testing.
Owner:BECKMAN COULTER INC
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.
Owner:ZYMEWORKS BC INC
Anti-p-selectin antibodies and methods of their use and identification
ActiveUS20110293617A1Reduce vasoocclusionImprove the level ofAnimal cellsFungiP-selectinBinding domain
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin / PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin / PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Owner:SELEXYS PHARMA CORP +1
Single-chain antibody against fenitrothion and preparation method thereof
InactiveCN102229672AStrong specificityHigh affinityMicroorganism based processesImmunoglobulinsEscherichia coliSingle-Chain Antibodies
The invention relates to a single-chain antibody against fenitrothion and a preparation method thereof. A ribosome display library of a whole set of single-chain antibody genes against the fenitrothion is constructed by using a ribosome display technology and rounding a hybrid tumor technology, and three single-chain antibody genes with high affinity and high specificity for the fenitrothion are screened from the library. After the single-chain antibody genes are connected with vectors PPOW3.0 and then subjected to soluble expression in escherichia coli, three soluble proteins with molecular weights of about 30KDa are obtained; and by enzyme-linked immuno sorbent assay (ELISA) and Biacore analysis, the three antibody proteins have high affinity and high specificity for the fenitrothion, so excellent single-chain antibody genes and antibody proteins are provided for establishing ELISA and immune sensors. The invention has significance for realizing quick, simple, convenient and accurate detection of organic phosphorus pesticide residue, and provides a new direction.
Owner:CHONGQING UNIV
Monoclonal antibody capable of antagonizing and inhibiting bonding of programmed death-1 receptor (PD-1) and ligand thereof as well as encoding sequence and use of monoclonal antibody
ActiveCN104558177AAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsProtein detectionHeavy chain
Disclosed in the present invention are a mouse monoclonal antibody for antagonizing and inhibiting the binding of a programmed death-1 (PD-1) to the ligand thereof, and the heavy chain variable region and light chain variable region amino acid sequences thereof. Also disclosed in the present invention is a DNA molecule nucleotide sequence encoding the heavy chain variable region and light chain variable region of the antibody. Also disclosed in the present invention are a method for preparing a human-mouse chimeric antibody of the antibody and derivatives thereof, and the use thereof in PD-1 protein detection.
Owner:ACROIMMUNE BIOTECH CO LTD
Methods and compositions for identifying d-peptidic compounds that specifically bind target proteins
Methods and compositions for identifying D-peptidic compounds that specifically bind target proteins are provided. Aspects of the methods include screening libraries of 20 residue or more L-peptidic compounds for specific binding to 40 residue or more D-target proteins. Once a L-peptidic compound has been identified that specifically binds to the D-target protein, the D-enantiomer of that compound may be produced.
Owner:THE GOVERNINIG COUNCIL OF THE UNIV OF TORANTO +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com